Histamine Intolerance Through a Functional Medicine Lens: A Systems-Based Review

June 16, 2026 Dick Benson 2026 AIC 0

Elena Colussi-Pelaez, MD

 

Elena Colussi-Pelaez, MD, Preventive Medicine Resident Physician, Loma Linda University Health, Loma Linda, California, USA.

 

Corresponding author: Elena Colussi-Pelaez, MD 

E-mail: EColussiPelaez@llu.edu

 

Keywords: Histamine intolerance, Diamine oxidase, Low-histamine diet, Gut microbiome, Functional medicine.

 

 

Introduction

Histamine intolerance (HIT) is an increasingly recognized clinical syndrome characterized by an imbalance between histamine accumulation and an individual’s capacity for degradation.1,2 Patients frequently present with gastrointestinal, dermatologic, neurologic, and systemic symptoms, including flushing, headaches, urticaria, and gastrointestinal distress.1,3 Despite growing awareness, HIT remains underdiagnosed, as standardized diagnostic criteria and evidence-based treatment pathways are yet to be established.1,4,5 Symptom overlap with migraine, chronic urticaria, and functional gastrointestinal disorders contributes to a substantial clinical burden.2,6,7 Diamine oxidase (DAO) and histamine-N-methyltransferase (HNMT) are the primary enzymes responsible for histamine metabolism, and reduced activity, whether due to genetic variants, intestinal mucosal injury, medication effects, or nutrient insufficiencies, may contribute to symptom expression.1,8,9

Conventional approaches often target isolated symptoms rather than underlying mechanisms. Functional medicine (FM) offers a systems-based framework that emphasizes root-cause assessment, personalization, and modifiable lifestyle interventions.

This review synthesizes current evidence on HIT pathophysiology, diagnostic challenges, and therapeutic strategies through an FM lens.

 

Methods

A literature review was conducted using PubMed, Embase, and Google Scholar in November 2025, with a targeted update in January 2026. Studies examining HIT, histamine metabolism, DAO activity, dietary interventions, microbiome associations, and clinical outcomes were included; articles focused solely on acute histamine intoxication were excluded. Findings were synthesized using FM principles, including a systems-based approach, the antecedents, triggers, and mediators (ATMs) framework, modifiable lifestyle factors, and personalization. The review prioritized peer-reviewed human data and clinically relevant outcomes.

 

Main Narrative

HIT reflects interconnected dysfunction across immune, gastrointestinal, neurologic, and detoxification systems.1,2 Impaired intestinal DAO activity limits first-pass histamine degradation, while disruption of intestinal barrier integrity, gut microbial composition, and low-grade mucosal inflammation may amplify histamine burden by impairing enterocyte function, reducing DAO expression, promoting mast cell activation, and increasing epithelial permeability.10-13

The ATM framework offers a useful structure for understanding drivers of HIT. Antecedents include genetic susceptibility, atopic disease, early-life gut dysbiosis, chronic inflammatory states, and intestinal pathologies such as celiac disease.15 Genetic variants affecting DAO and HNMT, along with immune activation and mast cell hyperreactivity, may further potentiate histamine release.9,14 Triggers reported include high-histamine foods, histamine liberators, alcohol, fermented foods, stress, infections, and DAO-inhibiting medications.1,16 Mediators include impaired epithelial integrity, mast cell activation, nutrient insufficiencies (e.g., vitamin B6, copper, zinc), and microbiome imbalances contributing to endogenous histamine production.11,14,16 Hormonal fluctuations, including menstrual cycle phase, have also been associated with variation in serum DAO activity and symptom severity, suggesting an additional layer of personalization in susceptible individuals.22

Growing evidence suggests that HIT is associated with characteristic alterations in gut microbial composition.11,12 Over 100 bacterial species have been identified in the human gut microbiome, capable of producing histamine via histidine decarboxylase pathways.13 Studies have reported an increased abundance of histamine-producing bacteria, including members of the Enterobacteriaceae family and genera such as Proteus and Staphylococcus, alongside reduced proportions of bacteria commonly associated with gut health, including Prevotellaceae, Faecalibacterium, and Bifidobacterium.11,12 These microbial patterns are frequently accompanied by reduced alpha diversity and elevated stool zonulin levels, suggesting concomitant intestinal barrier dysfunction.11,12 Dysbiosis may influence both histamine production and degradation, contributing to a bidirectional relationship between microbial imbalance, mucosal integrity, and symptom expression.2,11

Nutrition remains the most consistently supported intervention in HIT. Low-histamine diets are associated with reductions in gastrointestinal, dermatologic, and neurologic symptoms, with improvements often observed within 2-8 weeks.17-21 Preliminary data suggest dietary histamine reduction may also reduce histamine-producing gut bacteria and influence serum DAO levels.22-24

Histamine functions as a key wake-promoting neurotransmitter, and dysregulation of histaminergic neurons has been linked to hyper-arousal, sleep fragmentation, and circadian disruption.25,26 Chronic stress and sleep disturbance may increase mast cell activation and histamine release, suggesting a mechanistic link between neuroimmune signalling and symptom expression.27,28 Circadian disruption has also been associated with altered timing of histamine release from mast cells.29 While direct clinical trials on sleep or stress interventions in HIT remain limited, these findings support optimizing sleep-wake timing and stress resilience as strategies complementing nutrition-focused care within an FM framework.

Physical activity modulates histamine physiology by inducing both release and synthesis of histamine in skeletal muscle, contributing to post-exercise vasodilation and adaptive gene expression.30,31 Intramuscular histamine levels may increase substantially during activity, via heat-activated histidine decarboxylase pathways.32,33 While physiologically beneficial in healthy individuals, excess histamine signalling may contribute to heightened pain sensitivity and post-exertional discomfort in susceptible populations,34 and in those with impaired histamine metabolism or mast cell-related conditions, may extend systemically, contributing to symptoms such as flushing or gastrointestinal distress.35 These findings support a personalized approach emphasizing graded intensity, adequate recovery, and symptom-guided progression rather than activity avoidance.

Several studies report symptom improvement following DAO supplementation, particularly among individuals with low baseline DAO activity, though available evidence remains limited.2,36-39 Progressive food reintroduction, symptom tracking, targeted testing, and microbiome-informed interventions support individualized care while minimizing unnecessary dietary restriction, with therapeutic partnership central to long-term adherence.

Emerging strategies targeting gut dysbiosis and intestinal barrier integrity are being explored as adjunctive approaches, though direct clinical trials remain limited. Probiotic interventions require careful strain selection, as certain histamine-producing Lactobacillus species may exacerbate symptoms, whereas Bifidobacterium-dominant formulations may help restore microbial balance.11,40 Prebiotics such as fructooligosaccharides and fermentable fibres may support short-chain fatty acid production, epithelial integrity, and immune regulation,40,41 and dietary patterns emphasizing fibre diversity, polyphenol intake, and anti-inflammatory nutrition may further support microbiome resilience.41 Although synbiotic combinations theoretically offer synergistic benefits, evidence specific to HIT remains largely extrapolated from broader microbiome research.2,11 Together, these strategies reflect a systems-oriented approach focused on restoring microbial balance and intestinal barrier function while acknowledging significant gaps in HIT-specific clinical evidence.

 

Conclusion

HIT represents a multisystem condition influenced by genetic susceptibility, gut integrity, immune activation, and lifestyle factors. An FM approach emphasizes identification of ATMs while recognizing the interconnectedness of physiologic systems. Current evidence supports low-histamine, anti-inflammatory nutrition as foundational, with DAO supplementation and microbiome-directed interventions as adjunctive options, guided by individual clinical presentation. Attention to individual variability, sleep quality, stress resilience, and progressive dietary reintroduction may further support symptom stability. Future research should prioritize standardized diagnostic criteria, validated symptom measures, and controlled trials evaluating personalized, systems-oriented interventions.

 

Funding

No external funding was received for this study.

References

  1. Kovacova-Hanuskova E, Buday T, Gavliakova S, Plevkova J. Histamine, histamine intoxication and intolerance. Allergol Immunopathol (Madr). 2015;43(5):498-506. doi:10.1016/j.aller.2015.05.001
  2. Comas-Basté O, Sánchez-Pérez S, Veciana-Nogués MT, Latorre-Moratalla M, Vidal-Carou MDC. Histamine intolerance: the current state of the art. Biomolecules. 2020;10(8):1181. doi:10.3390/biom10081181
  3. Schnedl WJ, Lackner S, Enko D, Schenk M, Holasek SJ, Mangge H. Evaluation of symptoms and symptom combinations in histamine intolerance. Intest Res. 2019;17(3):427-433. doi:10.5217/ir.2018.00152
  4. Tamasi J, Kalabay L. Spectrum, time course, stages, and a proposal for the diagnosis of histamine intolerance in general practice: a nonrandomized, quasi-experimental study. J Clin Med. 2025;14(2):311. doi:10.3390/jcm14020311
  5. Alemany-Fornés M, Bori J, Muguerza B, Suárez M. Diamine oxidase deficiency implications for health, current management, and future directions in the treatment of histamine intolerance: A review. Int J Biol Macromol. 2025;327(Pt 1):147130. doi:10.1016/j.ijbiomac.2025.147130
  6. Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34. doi:10.1186/s10194-022-01402-2
  7. Siebenhaar F, Melde A, Magerl M, Zuberbier T, Church MK, Maurer M. Histamine intolerance in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2016;30(10):1774-1777. doi:10.1111/jdv.13778
  8. Manzotti G, Breda D, Di Gioacchino M, Burastero SE. Serum diamine oxidase activity in patients with histamine intolerance. Int J Immunopathol Pharmacol. 2016;29(1):105-111. doi:10.1177/0394632015617170
  9. Maintz L, Benfadal S, Allam JP, Hagemann T, Fimmers R, Novak N. Evidence for a reduced histamine degradation capacity in a subgroup of patients with atopic eczema. J Allergy Clin Immunol. 2006;117(5):1106-1112. doi:10.1016/j.jaci.2005.11.041
  10. Schnedl WJ, Enko D. Histamine intolerance originates in the gut. Nutrients. 2021;13(4):1262. doi:10.3390/nu13041262
  11. Schink M, Konturek PC, Tietz E, et al. Microbial patterns in patients with histamine intolerance. J Physiol Pharmacol. 2018;69(4). doi:10.26402/jpp.2018.4.09
  12. Sánchez-Pérez S, Comas-Basté O, Duelo A, et al. Intestinal dysbiosis in patients with histamine intolerance. Nutrients. 2022;14(9):1774. doi:10.3390/nu14091774
  13. Mou Z, Yang Y, Hall AB, Jiang X. The taxonomic distribution of histamine-secreting bacteria in the human gut microbiome. BMC Genomics. 2021;22(1):695. doi:10.1186/s12864-021-08004-3
  14. Smolinska S, Jutel M, Crameri R, O’Mahony L. Histamine and gut mucosal immune regulation. Allergy. 2014;69(3):273-281. doi:10.1111/all.12330
  15. Zhao Y, Zhang X, Jin H, Chen L, Ji J, Zhang Z. Histamine intolerance—a kind of pseudoallergic reaction. Biomolecules. 2022;12(3):454. doi:10.3390/biom12030454
  16. Hrubisko M, Danis R, Huorka M, Wawruch M. Histamine intolerance—the more we know the less we know. A review. Nutrients. 2021;13(7):2228. doi:10.3390/nu13072228
  17. Wantke F, Götz M, Jarisch R. Histamine-free diet: treatment of choice for histamine-induced food intolerance and supporting treatment for chronic headaches. Clin Exp Allergy. 1993;23(12):982-985. doi:10.1111/j.1365-2222.1993.tb00287.x
  18. Vickerstaff Joneja JM, Carmona-Silva C. Outcome of a histamine-restricted diet based on chart audit. J Nutr Environ Med. 2001;11(3):249-262. doi:10.1080/13590840120103094
  19. Son JH, Chung BY, Kim HO, Park CW. A histamine-free diet is helpful for treatment of adult patients with chronic spontaneous urticaria. Ann Dermatol. 2018;30(2):164-172. doi:10.5021/ad.2018.30.2.164
  20. Kohn JB. Is there a diet for histamine intolerance? J Acad Nutr Diet. 2014;114(11):1860. doi:10.1016/j.jand.2014.09.009
  21. Wagner N, Dirk D, Peveling-Oberhag A, et al. A Popular myth – low-histamine diet improves chronic spontaneous urticaria – fact or fiction? J Eur Acad Dermatol Venereol. 2017;31(4):650-655. doi:10.1111/jdv.13966
  22. Jackson K, Busse W, Gálvez-Martín P, Terradillos A, Martínez-Puig D. Evidence for dietary management of histamine intolerance. Int J Mol Sci. 2025;26(18):9198. doi:10.3390/ijms26189198
  23. Sánchez-Pérez S, Comas-Basté O, Duelo A, et al. The dietary treatment of histamine intolerance reduces the abundance of some histamine-secreting bacteria of the gut microbiota in histamine intolerant women. A pilot study. Front Nutr. 2022;9:1018463. doi:10.3389/fnut.2022.1018463
  24. Lackner S, Malcher V, Enko D, Mangge H, Holasek SJ, Schnedl WJ. Histamine-reduced diet and increase of serum diamine oxidase correlating to diet compliance in histamine intolerance. Eur J Clin Nutr. 2019;73(1):102-104. doi:10.1038/s41430-018-0260-5
  25. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88(3):1183-1241. doi:10.1152/physrev.00043.2007
  26. Thakkar MM. Histamine in the regulation of wakefulness. Sleep Med Rev. 2011;15(1):65-74. doi:10.1016/j.smrv.2010.06.004
  27. Nishino S, Sakai N, Nishino N, Ono T. Brain mast cells in sleep and behavioral regulation. Curr Top Behav Neurosci. 2022;59:427-446. doi:10.1007/7854_2022_359
  28. Eutamene H, Theodorou V, Fioramonti J, Bueno L. Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats. J Physiol. 2003;553(Pt 3):959-966. doi:10.1113/jphysiol.2003.052274
  29. Nakao A, Nakamura Y. Time will tell about mast cells: circadian control of mast cell activation. Allergol Int. 2022;71(4):425-431. doi:10.1016/j.alit.2022.06.008
  30. Luttrell MJ, Halliwill JR. The intriguing role of histamine in exercise responses. Exerc Sport Sci Rev. 2017;45(1):16-23. doi:10.1249/JES.0000000000000093
  31. Sieck DC, Kobak SH, Larson EA, et al. Histamine is a molecular transducer of adaptation to endurance exercise training in humans. J Appl Physiol. 2025;138(6):1398-1410. doi:10.1152/japplphysiol.00687.2024
  32. Van der Stede T, Blancquaert L, Stassen F, et al. Histamine H1and H2receptors are essential transducers of the integrative exercise training response in humans. Sci Adv. 2021;7(16):eabf2856. doi:10.1126/sciadv.abf2856
  33. Mangum JE, Needham KW, Sieck DC, et al. The effect of local passive heating on skeletal muscle histamine concentration: implications for exercise-induced histamine release. J Appl Physiol. 2022;132(2):367-374. doi:10.1152/japplphysiol.00740.2021
  34. Ely MR, Romero SA, Sieck DC, Mangum JE, Luttrell MJ, Halliwill JR. A single dose of histamine-receptor antagonists before downhill running alters markers of muscle damage and delayed-onset muscle soreness. J Appl Physiol. 2017;122(3):631-641. doi:10.1152/japplphysiol.00518.2016
  35. Kulinski JM, Metcalfe DD, Young ML, et al. Elevation in histamine and tryptase following exercise in patients with mastocytosis. J Allergy Clin Immunol Pract. 2019;7(4):1310-1313.e2. doi:10.1016/j.jaip.2018.07.008
  36. Yacoub MR, Ramirez GA, Berti A, et al. Diamine oxidase supplementation in chronic spontaneous urticaria: a randomized, double-blind placebo-controlled study. Int Arch Allergy Immunol. 2018;176(3-4):268-271. doi:10.1159/000488142
  37. Izquierdo-Casas J, Comas-Basté O, Latorre-Moratalla ML, et al. Diamine oxidase (DAO) supplement reduces headache in episodic migraine patients with DAO deficiency: A randomized double-blind trial. Clin Nutr. 2019;38(1):152-158. doi:10.1016/j.clnu.2018.01.013
  38. Schnedl WJ, Schenk M, Lackner S, Enko D, Mangge H, Forster F. Diamine oxidase supplementation improves symptoms in patients with histamine intolerance. Food Sci Biotechnol. 2019;28(6):1779-1784. doi:10.1007/s10068-019-00627-3
  39. Jochum C. Histamine intolerance: symptoms, diagnosis, and beyond. Nutrients. 2024;16(8):1219. doi:10.3390/nu16081219
  40. Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16(10):605-616. doi:10.1038/s41575-019-0173-3
  41. Jawhara S. Healthy diet and lifestyle improve the gut microbiota and help combat fungal infection. Microorganisms. 2023;11(6):1556. doi:10.3390/microorganisms11061556

Be the first to comment

Leave a Reply

Your email address will not be published.


*